Wall Street analysts forecast that Amarin Co. plc (NASDAQ:AMRN) will post earnings of ($0.05) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Amarin’s earnings. Amarin reported earnings per share of ($0.08) during the same quarter last year, which would indicate a positive year-over-year growth rate of 37.5%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Amarin will report full-year earnings of ($0.29) per share for the current financial year. For the next financial year, analysts expect that the firm will report earnings of ($0.07) per share. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Amarin.
A number of analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 target price on shares of Amarin in a research report on Friday, December 14th. BidaskClub raised Amarin from a “hold” rating to a “buy” rating in a research report on Friday, October 26th. Citigroup reaffirmed a “buy” rating and set a $25.00 target price (up from $17.00) on shares of Amarin in a research report on Tuesday, October 16th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 target price on shares of Amarin in a research report on Thursday, January 17th. Finally, Zacks Investment Research lowered Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $33.20.
NASDAQ:AMRN traded up $0.66 during mid-day trading on Friday, hitting $16.81. The company had a trading volume of 5,706,133 shares, compared to its average volume of 7,207,824. Amarin has a 1 year low of $2.35 and a 1 year high of $23.33. The firm has a market capitalization of $5.22 billion, a PE ratio of -67.24 and a beta of 1.16.
In related news, insider John F. Thero sold 607,611 shares of Amarin stock in a transaction dated Monday, November 12th. The stock was sold at an average price of $19.07, for a total value of $11,587,141.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Steven B. Ketchum sold 17,042 shares of Amarin stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $17.79, for a total value of $303,177.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,682,380 shares of company stock worth $45,192,992. Corporate insiders own 4.08% of the company’s stock.
A number of large investors have recently bought and sold shares of AMRN. Benjamin F. Edwards & Company Inc. acquired a new position in Amarin in the fourth quarter worth about $34,000. Lindbrook Capital LLC acquired a new position in Amarin in the fourth quarter worth about $40,000. IFP Advisors Inc grew its stake in Amarin by 71.2% in the fourth quarter. IFP Advisors Inc now owns 8,413 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 3,500 shares in the last quarter. Signature Estate & Investment Advisors LLC grew its stake in Amarin by 17.8% in the fourth quarter. Signature Estate & Investment Advisors LLC now owns 9,920 shares of the biopharmaceutical company’s stock worth $135,000 after purchasing an additional 1,500 shares in the last quarter. Finally, FNY Investment Advisers LLC grew its stake in Amarin by 199,900.0% in the fourth quarter. FNY Investment Advisers LLC now owns 10,000 shares of the biopharmaceutical company’s stock worth $136,000 after purchasing an additional 9,995 shares in the last quarter. Institutional investors and hedge funds own 42.34% of the company’s stock.
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also: What is Depreciation?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.